Patients with primary advanced/recurrent endometrial carcinoma may now receive pembrolizumab plus chemotherapy as indicated by the FDA.
Approval Alert | Pembrolizumab/Chemotherapy in Advanced/Recurrent Endometrial Carcinoma
Advertisement
Advertisement
Trending on CancerNetwork
1
ASCENT-03 Trial Supports Standard Use of Sacituzumab Govitecan in mTNBC
2
Pembrolizumab Combo Significantly Improves PFS/OS in Recurrent PROC
3
TUB-040 Elicits Early Responses in Platinum-Resistant Ovarian Cancer
4
Tarlatamab Improves Survival Vs Chemotherapy in Second-Line SCLC Subgroups
5
